Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius OncologyCTOR -0.92%10 EV-to-OCF is -6.59 as of Aug. 10, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Citius Oncology ranks better than 78.33% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Citius Oncology's Enterprise Value is $73.69 Mil.
Citius Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.19 Mil. Therefore, Citius Oncology's EV-to-OCF for today is -6.59.
The historical rank and industry rank for Citius Oncology's EV-to-OCF or its related term are showing as below:
CTOR'
s EV-to-OCF Range Over the Past 10 Years
Min: -14.03 Med: -7.78 Max: -5.13
Current: -6.59
During the past 4 years, the highest EV-to-OCF of Citius Oncology was -5.13. The lowest was -14.03. And the median was -7.78.
CTOR's EV-to-OCF is ranked better than 78.33% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.06
vs CTOR: -6.59
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Citius Oncology's PE Ratio (TTM) for today is calculated as:
Citius Oncology's share price for today is $0.78.
Citius Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Citius Oncology EV-to-OCF Related Terms
Citius Oncology EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Citius Oncology's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Citius Oncology's EV-to-OCF falls into.
Citius Oncology's current Enterprise Value is $73.69 Mil.
Citius Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a EV-to-OCF of -6.59 as of Aug. 10, 2026. According to the industry distribution chart, Citius Oncology ranks #218 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 21.7%.
Is Citius Oncology's EV-to-OCF too high?
Citius Oncology's current EV-to-OCF is -6.59. Based on the distribution chart, Citius Oncology ranks #218 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's EV-to-OCF compare to INCR and CPHI?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #218 out of 1006 companies for EV-to-OCF. This places Citius Oncology in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 11.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.06, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current EV-to-OCF is -6.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current EV-to-OCF of -6.59. The current EV-to-OCF is -6.59. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Citius Oncology (CTOR), the current EV-to-OCF is -6.59 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
